Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP16 vs EU-Prolia in Post-Menopausal Osteoporosis
2023-503790-37-00Phase 3Completed
- Sponsor
- CuraTeQ Biologics
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of DenOsteoRel in postmenopausal osteoporosis and osteoporosis (2 arms), sponsored by CuraTeQ Biologics. Primary endpoints: Percent change from baseline in lumbar spine bone mineral density at Week 52 and AUEC of serum C-terminal telopeptide from Week 0 to Week 26. Started Jan 2024; status: completed.
02
Drugs
DenOsteoRel
03
Conditions
postmenopausal osteoporosisosteoporosis
Beyond the preview
Go deeper on 2023-503790-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503790-37-00.